Lombardi Comprehensive Cancer Center Clinical Trials Protocol

Cancer Type: Pancreas

Hospitals offering this trial


2009-608
A Phase I/II Study of ABT-888 in Combination with 5-Fluorouracil and Oxaliplatin (modified FOLFOX6) in Patients with Metastatic Pancreatic Cancer  

Forms:

 
Georgetown University Hospital Franklin Square Hospital Center Good Samaritan Hospital Harbor Hospital Union Memorial Hospital Washington Hospital Center
 

People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with metastatic pancreatic cancer. ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body. ABT-888 is an investigational or experimental anti-cancer agent that has not yet been approved by the Food and Drug Administration (FDA) for use in pancreatic cancer.

Contact: Lombardi Cancer Line
Email: LombardiCancerLine@gunet.georgetown.edu
Phone: 202-444-4000


 

2011-384
A Pilot Study of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Cancer 

Forms:

 
Georgetown University Hospital Franklin Square Hospital Center Good Samaritan Hospital Harbor Hospital Union Memorial Hospital Washington Hospital Center
 

This study is for patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to determine whether molecularly tailored therapy can improve the effectiveness of standard chemotherapy combinations for patients with metastatic pancreatic cancer. A series of special tests will be performed on a sample of tumor, and based on the results subjects will be assigned to one of seven chemotherapy treatments, with each being the combination of two standard chemotherapies. Each of these combinations has been safely used in patients with pancreatic or other types of cancer. The purpose of this study is to to determine the ability to personalize therapy in this manner, and to determine how many patients a larger study would need. A second purpose is not to determine if one doublet is better than another. Rather, this second purpose is to show that for all patients enrolled in this protocol who have been assigned a doublet based on their tumor's molecular analysis (molecular tailoring), treatment response will be better than would be expected compared to patients who have been treated in the past with no molecular tailoring.

Contact: Lisa Ley
Email: leyl@georgetown.edu
Phone: 202-687-6653


 

2013-0138
A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients with Metastatic Pancreatic Cancer

Forms:

 
Georgetown University Hospital Franklin Square Hospital Center Good Samaritan Hospital Harbor Hospital Union Memorial Hospital Washington Hospital Center
 

The purpose of this study is to evaluate the clinical activity of the combination of gemcitabine and nab-paclitaxel as second line treatment in patients with metastatic pancreatic cancer who have received non-gemcitabine-based chemotherapy in the first line setting.

Contact: Lisa Ley
Email: leyl@georgetown.edu
Phone: 202-687-6653


 

Pro-063
A Phase II Study of Dovitinib as Maintenance and Adjuvant Therapy in Patients with Colorectal and Pancreas Cancers.

This study is for patients with stage 4 colon cancer who have had initial chemotherapy or had surgery to remove metastases and patients with pancreas cancer, which has been surgically removed and are receiving adjuvant chemotherapy or is locally advanced and have already received chemotherapy and radiation.

The purpose of this study is to determine the effects of oral dovitinib in patients with advanced stage colorectal and pancreas. Dovitinib will be taken by mouth for 5 days out of every week for up to 2 years.

Forms:

Contact
Email: kd252@georgetown.edu
Phone: 202-687-6974